Payment overview · 2025
General Payments
$954.16
52 reported records · 20 companies
Healthcare provider profile · identity verified
Hima Bindu Ravi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LUBBOCK, TX · NPI 1326147158
Verified facts
What the public records show
CMS Open Payments records show Hima Bindu Ravi, MD received $954.16 in general payments during 2025 across 52 reported records.
Amgen Inc. accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.59 | 14.9% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.21 | 12.7% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $113.87 | 11.9% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $92.52 | 9.7% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $80.84 | 8.5% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $67.53 | 7.1% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.05 | 4.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.24 | 3.7% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $32.61 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.80 | 3.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.54 | 2.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.38 | 2.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.84 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.76 | 2.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $20.56 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.67 | 1.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.78 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.07 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.79 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.51 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $954.16 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.21 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $121.21 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.87 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $113.87 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $95.34 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $92.52 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $84.98 | 6 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $80.84 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $67.53 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.05 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.24 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.24 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $32.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.62 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 210 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 141 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 96 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
141 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
210 | 59 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1096 | 281 |
| Atorvastatin Calcium | Atorvastatin Calcium | 791 | 264 |
| Gabapentin | Gabapentin | 748 | 241 |
| Amlodipine Besylate | Amlodipine Besylate | 709 | 189 |
| Furosemide | Furosemide | 665 | 191 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 606 | 186 |
| Pantoprazole Sodium | Pantoprazole Sodium | 598 | 187 |
| Potassium Chloride | Potassium Chloride | 558 | 172 |
| Metoprolol Succinate | Metoprolol Succinate | 550 | 175 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 546 | 80 |
| Lisinopril | Lisinopril | 497 | 148 |
| Tramadol Hcl | Tramadol Hcl | 480 | 146 |
| Metformin Hcl | Metformin Hcl | 415 | 115 |
| Losartan Potassium | Losartan Potassium | 384 | 124 |
| Pravastatin Sodium | Pravastatin Sodium | 346 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 321 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 86 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 280 | 84 |
| Tizanidine Hcl | Tizanidine Hcl | 272 | 91 |
| Meloxicam | Meloxicam | 264 | 100 |
| Metoprolol Tartrate | Metoprolol Tartrate | 258 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 243 | 62 |
| Alendronate Sodium | Alendronate Sodium | 229 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 226 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 72 |
| Omeprazole | Omeprazole | 223 | 71 |
| Eliquis | Apixaban | 210 | 59 |
| Trazodone Hcl | Trazodone Hcl | 192 | 60 |
| Simvastatin | Simvastatin | 191 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 189 | 130 |
| Metformin Hcl Er | Metformin Hcl | 188 | 54 |
| Alprazolam | Alprazolam | 185 | 32 |
| Donepezil Hcl | Donepezil Hcl | 180 | 55 |
| Allopurinol | Allopurinol | 173 | 46 |
| Finasteride | Finasteride | 173 | 47 |
| Carvedilol | Carvedilol | 167 | 50 |
| Montelukast Sodium | Montelukast Sodium | 160 | 47 |
| Glimepiride | Glimepiride | 155 | 50 |
| Mirtazapine | Mirtazapine | 146 | 58 |
| Buspirone Hcl | Buspirone Hcl | 145 | 52 |
| Mounjaro | Tirzepatide | 141 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 137 | 44 |
| Levetiracetam | Levetiracetam | 135 | 28 |
| Sertraline Hcl | Sertraline Hcl | 135 | 34 |
| Amoxicillin | Amoxicillin | 134 | 103 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 130 | 40 |
| Glipizide Er | Glipizide | 129 | 40 |
| Azithromycin | Azithromycin | 125 | 96 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 120 | 30 |
| Glipizide | Glipizide | 117 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 47 |
| Liothyronine Sodium | Liothyronine Sodium | 109 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 101 | 26 |
| Gemfibrozil | Gemfibrozil | 101 | 28 |
| Methylprednisolone | Methylprednisolone | 100 | 76 |
| Irbesartan | Irbesartan | 99 | 31 |
| Memantine Hcl | Memantine Hcl | 96 | 26 |
| Ozempic | Semaglutide | 96 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 69 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 32 |
| Clonidine Hcl | Clonidine Hcl | 92 | 37 |
| Clonazepam | Clonazepam | 91 | 29 |
| Ramipril | Ramipril | 88 | 27 |
| Celecoxib | Celecoxib | 86 | 31 |
| Spironolactone | Spironolactone | 85 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 80 | 53 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 50 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 69 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 79 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 79 | 24 |
| Telmisartan | Telmisartan | 78 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 29 |
| Cephalexin | Cephalexin | 74 | 60 |
| Lorazepam | Lorazepam | 74 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 72 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 26 |
| Lovastatin | Lovastatin | 71 | 22 |
| Methocarbamol | Methocarbamol | 70 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 26 |
| Estradiol | Estradiol | 68 | 22 |
| Entresto | Sacubitril/Valsartan | 67 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 22 |
| Meclizine Hcl | Meclizine Hcl | 65 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 19 |
| Lactulose | Lactulose | 64 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 16 |
| Gemtesa | Vibegron | 63 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 63 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 21 |
| Naproxen | Naproxen | 61 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 32 |
| Pregabalin | Pregabalin | 60 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 17 |
| Nystatin | Nystatin | 59 | 40 |
| Prednisone | Prednisone | 59 | 41 |
| Sucralfate | Sucralfate | 59 | 17 |
| Synthroid | Levothyroxine Sodium | 59 | 17 |
| Xarelto | Rivaroxaban | 59 | 13 |
| Januvia | Sitagliptin Phosphate | 57 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 57 | 22 |
| Diazepam | Diazepam | 56 | 11 |
| Jardiance | Empagliflozin | 55 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 53 | 14 |
| Atenolol | Atenolol | 53 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 16 |
| Promethazine Hcl | Promethazine Hcl | 53 | 18 |
| Nabumetone | Nabumetone | 52 | 15 |
| Enalapril Maleate | Enalapril Maleate | 51 | 15 |
| Bupropion Xl | Bupropion Hcl | 50 | 15 |
| Levofloxacin | Levofloxacin | 50 | 37 |
| Bumetanide | Bumetanide | 49 | 16 |
| Valsartan | Valsartan | 49 | 18 |
| Chlorthalidone | Chlorthalidone | 48 | 11 |
| Propranolol Hcl | Propranolol Hcl | 46 | 15 |
| Primidone | Primidone | 45 | 11 |
| Famotidine | Famotidine | 44 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 14 |
| Nifedipine Er | Nifedipine | 44 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 22 |
| Lansoprazole | Lansoprazole | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | suppressed |
| Trulicity | Dulaglutide | 42 | 13 |
| Ondansetron Odt | Ondansetron | 41 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 16 |
| Ezetimibe | Ezetimibe | 40 | 15 |
| Lacosamide | Lacosamide | 40 | suppressed |
| Linzess | Linaclotide | 39 | suppressed |
| Baclofen | Baclofen | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 13 |
| Fluconazole | Fluconazole | 37 | 22 |
| Latanoprost | Latanoprost | 37 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Multaq | Dronedarone Hcl | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Klor-Con 10 | Potassium Chloride | 29 | 13 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | 12 |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 12 |
| Olanzapine | Olanzapine | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 21 | 18 |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Famciclovir | Famciclovir | 17 | 14 |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 16 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 16 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Np Thyroid | Thyroid,pork | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $954.16 · 52 records | Amgen Inc. | AREXVY, BEXSERO, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GATTEX, GEMTESA, KRYSTEXXA, Kerendia, Korlym, Leqembi, MOUNJARO, NEXLETOL, NUZYRA, OTEZLA, Ohtuvayre, Ozempic, REPATHA, Rybelsus, SHINGRIX, Senza, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, YUPELRI, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error